What is MNDL Bio?
MNDL Bio operates at the intersection of artificial intelligence and molecular biology, specializing in the engineering of DNA sequences to enhance recombinant protein production. By deploying sophisticated machine learning models, the company addresses critical bottlenecks in the synthetic biology pipeline, such as low expression yields and protracted development timelines. Their technology is designed to optimize host-specific gene expression, thereby reducing the financial burden of R&D for clients in the pharmaceutical and industrial biotech sectors. Through its data-driven approach, MNDL Bio provides a scalable framework that transforms how biological systems are programmed, offering a distinct competitive advantage in an industry increasingly reliant on precision engineering and predictive analytics.
How much funding has MNDL Bio raised?
MNDL Bio has raised a total of $2M across 1 funding round:
Other Financing Round
$2M
Other Financing Round (2024): $2M with participation from CPT Capital and Earth & Beyond Ventures
Key Investors in MNDL Bio
CPT Capital
CPT Capital is an investment firm focused on the future of food and materials, specifically in the alternative protein sector. They partner with visionary founders and companies that utilize cutting-edge technologies to replace animals in the supply chain.
Earth & Beyond Ventures
Earth & Beyond Ventures is an early-stage venture capital fund that invests in Israeli DeepTech and SpaceTech startups from concept to creation. The firm focuses on sectors such as ClimateTech, Optics, Quantum, Materials Science, and Semiconductors.
What's next for MNDL Bio?
Looking ahead, the influx of capital will likely be directed toward expanding the company's computational infrastructure and broadening its portfolio of host-optimized design solutions. As MNDL Bio transitions into its next phase of growth, the focus will shift toward commercializing its proprietary algorithms and forging deeper partnerships within the global biotechnology ecosystem. The strategic backing received will enable the firm to refine its predictive capabilities, potentially reducing time-to-market for its clients while maintaining a lean operational model. By prioritizing innovation in gene expression design, MNDL Bio is poised to become an essential utility for companies seeking to optimize their biological manufacturing processes in an increasingly complex regulatory and technical environment.
See full MNDL Bio company page
